Novartis Company Overview and History

Novartis has a rich history that spans over 250 years, dating back to 1797 when it was founded as a small chemical company in Basel, Switzerland. The company has undergone several transformations over the years.

In 1996, Novartis merged with Ciba-Geigy and Sandoz to form a single entity. This merger created a global pharmaceutical company with a diverse portfolio of products.

Today, Novartis is a leading global pharmaceutical company with a presence in over 140 countries. Its innovative medicines help patients with a range of diseases and conditions.

Novartis was created in March 1996 from the merger of Ciba-Geigy and Sandoz Laboratories, two Swiss companies. This marked the beginning of a new chapter in the company's history.

The company's history is a rich tapestry of significant events, including mergers, acquisitions, and expansions. Here are some key events that highlight the company's growth and development:

These recent developments demonstrate the company's commitment to innovation and growth, and its willingness to partner with other organizations to achieve its goals.

In 1996, Ciba-Geigy merged with Sandoz to form Novartis, with the pharmaceutical and agrochemical divisions staying together.

The merger led to the spin-off of other Ciba-Geigy and Sandoz businesses as independent companies, including Ciba Specialty Chemicals.

Sandoz's Master Builders Technologies was sold off to SKW Trostberg A.G., a subsidiary of the German energy company VIAG.

Novartis acquired Advanced Accelerator Applications for $3.9 billion in 2017, paying a 47 percent premium.

The company acquired Amblyotech in April 2020.

In 2014, Novartis acquired CoStim Pharmaceuticals and the rights to market Ophthotech's Fovista outside the U.S. for up to $1 billion.

Novartis also acquired GlaxoSmithKline's cancer drug business for $16 billion in 2014.

In 2016, Novartis acquired Selexys Pharmaceuticals for $665 million.

The company acquired Encore Vision, gaining its principle compound EV06, a first-in-class topical therapy for presbyopia, in 2016.

In 2021, Novartis acquired Arctos Medical, broadening its optogenetics range.

The company purchased Gyroscope Therapeutics from Syncona Ltd. for up to $1.5 billion in 2021.

Suggestion: SpareBank 1 Nøtterøy–Tønsberg

In 2023, Novartis completed the spin-off of Sandoz as a stand-alone company.

The company sold its 15 ophthalmology drugs to JB Chemicals for ₹1,089 crore ($116 million) in 2023.

In 2025, Novartis announced the acquisition of Anthos Therapeutics for $925 million.

The company agreed to buy Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion in 2025.

Expand your knowledge: Golden 1 Credit Union

Novartis is a global leader in healthcare, with a strong presence in over 140 countries.

The company has a diverse portfolio of innovative medicines, with a focus on treating patients with serious and chronic diseases.

In 2020, Novartis reported revenues of $47.4 billion, with a significant portion coming from its innovative medicines segment.

Sandoz is the generic drugs division of Novartis. Sandoz Pharmaceuticals was a pharmaceutical company headquartered in Basel, Switzerland, and was best known for developing drugs such as Sandimmune for organ transplantation.

The company was founded in 1886 by Alfred Kern and Edouard Sandoz. The first dyes manufactured by them were alizarin blue and auramine.

Worth a look: Sandoz

Sandoz began producing the fever-reducing drug antipyrin in 1895. The company also began producing the sugar substitute saccharin in 1899.

In 1917, Arthur Stoll founded Sandoz's pharmaceutical department. He isolated ergotamine from ergot in 1918, which was eventually used to treat migraine and headaches.

Gynergen, a treatment for migraine and headaches, was introduced in 1921. Calcium-Sandoz was brought to market in 1929.

Sandoz also produced chemicals for textiles, paper, and leather, starting in 1929. The company began producing agricultural chemicals in 1939.

The psychedelic effects of lysergic acid diethylamide (LSD) were discovered at the Sandoz laboratories in 1943. Sandoz marketed the substance, known as Delysid, from 1947 through the mid-1960s as a psychiatric drug.

Sandoz withdrew the drug from the market in 1965. The company opened its first foreign offices in 1964.

Sandoz merged with Wander AG in 1967. The company acquired several other companies, including Delmark, Wasabröd, and Gerber Products Company.

A fire broke out in a production plant storage room in 1986, leading to the Sandoz chemical spill and the release of pesticide into the upper Rhine river.

Readers also liked: Meyer Brothers Drug Company

In 2011, the company launched a new mobile app that allowed users to access their data on-the-go.

The app was designed to be user-friendly and accessible, with a simple interface that made it easy for anyone to use.

By 2012, the company had expanded its services to include online backup and storage, allowing users to store and access their files from anywhere.

This move was a huge success, with many users taking advantage of the convenient and secure storage solution.

In 2013, the company introduced a new feature that allowed users to share files and folders with others, making collaboration easier than ever.

This feature was a game-changer for teams and businesses, enabling them to work together more efficiently.

By 2015, the company had grown significantly, with a large and loyal customer base.

The company continued to innovate and improve its services, releasing new features and updates regularly.

In 2017, the company introduced artificial intelligence-powered tools that helped users automate tasks and streamline their workflows.

These tools were a huge hit, with many users praising their efficiency and effectiveness.

Today, the company remains committed to providing its users with the best possible experience, with a focus on innovation and customer satisfaction.

Readers also liked: Access Bank Ghana Plc

Novartis shares have traded at over $104.72 per share as of January 31, 2025, and its market capitalization was valued at $210.39B.

The company's revenue has fluctuated over the years, but it's worth noting that in 2021, Novartis' revenue reached $51.626 billion.

Here's a breakdown of Novartis' revenue and net income from 2005 to 2024:

Novartis' net income has seen a significant increase in 2021, reaching $24.018 billion.

The company's employee count has decreased over the years, with 76,057 employees as of 2023.

Novartis has a significant global research presence through its Novartis Institutes for BioMedical Research (NIBR) in Cambridge, Massachusetts. NIBR focuses on various diseases, including tuberculosis, dengue, and malaria.

The company operates two research institutes within NIBR that specifically address diseases in the developing world. These institutes are the Novartis Institute for Tropical Diseases and the Novartis Vaccines Institute for Global Health.

Novartis is also involved in collaborative research projects, such as the InnoMed PredTox project, which explores non-clinical safety assessment. The company is expanding its activities in joint research projects with the Innovative Medicines Initiative of EFPIA and the European Commission.

Here's an interesting read: BCA Research

Novartis has a global research operation called Novartis Institutes for BioMedical Research (NIBR), which is headquartered in Cambridge, Massachusetts.

NIBR has two research institutes focused on diseases in the developing world: the Novartis Institute for Tropical Diseases and the Novartis Vaccines Institute for Global Health.

These institutes work on diseases such as tuberculosis, dengue, malaria, salmonella typhi (typhoid fever), and shigella.

Novartis is also involved in publicly funded collaborative research projects with other industrial and academic partners, such as the InnoMed PredTox project.

The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.

Novartis is using technology to make research more accessible, including video-based telemedicine visits with patients, which can reduce the need for physical travel to clinics.

Suggestion: OCTA Research

Understanding Pipeline Drugs is crucial for staying ahead in the market. Novartis AG has a range of products in its pipeline.

For more insights, see: Pembina Pipeline

Identifying these products can help you contend with shifting product portfolios. This is evident in the fact that Novartis AG's products will be commercialized.

Staying informed about pipeline drugs can give you a competitive edge. By knowing which products are being developed, you can make informed decisions about your business strategy.

Novartis AG is working on commercializing its pipeline products. This is a key aspect of its research and development efforts.

Novartis is a diversified company with a presence in multiple business segments. It's the world's largest company in the life sciences and agribusiness markets, and the second-largest pharmaceutical company by market cap in 2019.

The company's Innovative Medicines business is a major player in the pharmaceutical industry, with commercial units focused on global and US markets. Its Sandoz division is the world's second-largest generic drug company, with a strong presence in the biosimilars market.

Novartis has a significant consumer health business, with a portfolio of over 20 brands, including Excedrin, Theraflu, and Bufferin. In 2014, the company divested its consumer health section into a joint venture with GlaxoSmithKline, which was later acquired by GSK in 2018 for $13 billion.

Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group.

The company owns all its subsidiaries worldwide, directly or indirectly, and operates in the United States as Novartis Pharmaceuticals Corporation (NPC) headquartered in New Jersey.

Its businesses are divided into two operating divisions: Innovative Medicines and Sandoz (generics). Alcon, the eye-care division, was spun off into an independent company in April 2019.

In August 2022, Novartis announced plans to spin off Sandoz as part of restructuring, which was completed in October 2023.

Novartis operates directly through subsidiaries, each of which falls under one of the divisions, and is categorized as fulfilling one or more of the following functions: Holding/Finance, Sales, Production, and Research.

Novartis AG held 33.3 percent of the shares of Roche until 2022, but did not exercise control over Roche.

The company has two significant license agreements with Genentech, a Roche subsidiary, for Lucentis and Xolair.

A unique perspective: One Caribbean Media

Novartis is a giant in the life sciences and agribusiness markets, and it's also the second-largest pharmaceutical company by market cap in 2019.

The company has a diverse range of market segments, including Alcon, Sandoz, and Vaccines and Diagnostics Division. In 2019, Novartis completed the spin-off of Alcon as a separate commercial entity, and Sandoz was recognized as the world's second-largest generic drug company as of 2013.

Sandoz reported US$9.9 billion in net sales in 2018, and Novartis announced plans to spin off Sandoz by the second half of 2023. In contrast, the Vaccines and Diagnostics Division was sold to CSL's BioCSL operation in late 2015, and then the consumer healthcare joint venture vaccines division was sold to GlaxoSmithKline for US$13.0 billion in 2018.

Some of the notable brands under Novartis' Consumer segment include Excedrin and Theraflu, which are leading OTC brands, but sales have been slowed by problems at its key US manufacturing plant.

Here's a list of some of the notable brands under Novartis' Consumer segment:

Novartis has faced significant regulatory challenges, particularly in the area of corruption and compliance. The company was investigated by US and Greek authorities for allegedly bribing Greek public officials between 2006 and 2015, resulting in a settlement with the US Department of Justice and the US Securities and Exchange Commission.

Novartis paid $1.2 million to Michael Cohen's consulting firm, Essential Consultants, to help understand and influence the new administration's approach to drug pricing and regulation. This payment was made despite Novartis claiming it was not able to get the information it needed from the consultants, which turned out to be false.

The US Senate committee report "White House Access for Sale" revealed that Novartis' relationship with Cohen was longer and more detailed than initially stated, with then-CEO Joseph Jimenez and Cohen communicating via email multiple times in 2017.

You might enjoy: Worshipful Company of Management Consultants

India's patent laws have been under challenge in recent years due to concerns over the country's intellectual property (IP) framework.

The Indian Patent Office has been criticized for its slow processing of patent applications, with some cases taking up to 10 years or more to be resolved.

India's patent laws are governed by the Patents Act of 1970, which was amended in 2005 to comply with international standards.

Check this out: Yorkshire Patent Steam Wagon Co.

The amended law introduced product patents for pharmaceuticals and chemicals, but also included provisions that allow for compulsory licensing and parallel importation.

The Indian government has been under pressure from international trade agreements, particularly the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, to strengthen its IP framework.

India's patent laws have been challenged in the courts, with several high-profile cases involving pharmaceutical companies such as Bayer and Novartis.

The Indian Supreme Court has ruled in favor of the government in several cases, upholding the validity of compulsory licensing and parallel importation provisions.

The controversy surrounding India's patent laws has led to calls for reform and modernization of the IP framework to make it more business-friendly and aligned with international standards.

Discover more: Trade Republic

Novartis Pharmaceuticals Corporation agreed to pay $642 million to settle allegations under the False Claims Act in July 2020. This is a significant settlement, one of the largest of its kind against a pharmaceutical manufacturer at the time.

The allegations involved improper payments to patients and physicians, as well as sham "speaker programs" that were actually kickback schemes to get doctors to prescribe Novartis' drugs. These practices undermined federal health programs by encouraging the use of Novartis' higher-priced products.

In 2020, Novartis paid $642 million to settle these allegations, with $591 million resolving claims about kickbacks to doctors and $51.25 million resolving allegations about funneling money through charitable foundations to cover Medicare copays for patients.

The settlement highlights the importance of compliance in the pharmaceutical industry, where even small actions can have significant consequences.

Novartis has been committed to philanthropy for decades, with a notable example being their fight against leprosy. They've been providing free, multidrug therapy to all endemic countries since 2000.

Their dedication to eliminating leprosy is a testament to their commitment to making a positive impact on society.

Novartis has been actively seeking out partnerships to advance its research and development in various areas, including neurodegeneration treatment. BioArctic AB has entered a collaboration and license agreement with Novartis Pharma AG.

The deal includes a $30 million upfront payment, with potential future milestones and royalties. This highlights Novartis' commitment to investing in cutting-edge technologies and treatments.

BioArctic's BrainTransporter technology has the potential to revolutionize neurodegeneration treatment. This partnership further solidifies Novartis' position as a leader in the industry.

The most recent analyst rating on BioArctic AB Class B stock is a Buy with a SEK243.00 price target.